On March 19, 2025, MIRA Pharmaceuticals, Inc. signed a letter of intent to acquire SKNY Pharmaceuticals, which includes a $5 million cash infusion and aims to enhance MIRA's drug development pipeline with SKNY-1, a drug candidate for weight loss and smoking cessation.